vimarsana.com

Latest Breaking News On - Nexgen powder - Page 1 : vimarsana.com

NA Proactive news snapshot: Cloud DX Inc, New Oroperu Resources Inc, Todos Medical Ltd, Kainantu Resources Ltd, CleanSpark Inc, Arcadia Biosciences Inc UPDATE …

NA Proactive news snapshot: Cloud DX, New Oroperu Resources, Todos Medical, Kainantu Resources, CleanSpark UPDATE … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Cloud DX Inc (CVE:CDX) said Brad Miller, a director of the company (formerly Roosevelt Capital Group), as a result of the previously announced qualifying transaction and related transactions, had acquired beneficial ownership and control over 7,307,337 shares and 100,000 share purchase warrants issued to B and M Miller Equity Holdings Inc -  an entity controlled by Mr Miller. The shares and warrants were issued in exchange for the securities of Cloud Canada held by B&M prior to completion of the qualifying transaction. As a result of the qualifying transaction, B&M has ownership and control over 10.13% of the shares on a non-diluted basis and around 10.28% of the  shares on a partially diluted basis assuming t

NA Proactive news snapshot: The Good Shroom Co Inc, Golden Minerals Company, Codebase Ventures Inc, Vicinity Motor Corp …

NA Proactive news snapshot: The Good Shroom Co, Golden Minerals, Codebase Ventures, Vicinity Motor … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive The Good Shroom Co Inc. (CVE:MUSH), previously Cluny Capital Corp, (CVE:CLN.H), a Toronto Venture Exchange (TSX) capital pool company, has announced the completion of its qualifying transaction, which involved the amalgamation of Teonan Biomedical Inc. with the company s wholly-owned subsidiary, as part of a three-cornered amalgamation between the parties. Immediately prior to the transaction, the company was continued under the Canada Business Corporations Act, its outstanding common shares were consolidated on a 3 for 1 basis and, the company changed its name to The Good Shroom Co Inc. (Les Bons Champignons Inc.).

PyroGenesis Canada Inc says its Additive Manufacturing NexGen Powder production line now in place and producing powders

PyroGenesis says its Additive Manufacturing NexGen Powder production line now in place and producing powders NexGen Plasma Atomization System, with its production rate exceeding 25 kg/h, has shattered all published plasma-atomized production rates for titanium known to management Several major top-tier aerospace companies and OEMs, are awaiting powders from PyroGenesis’ new, state-of-the-art NexGen production line PyroGenesis Canada Inc (TSE:PYR) (NASDAQ:PYR) (FRA:8PY) has announced that its cutting-edge Additive Manufacturing (AM) NexGen Powder production line is now in place and producing powders.  The company said its NexGen Plasma Atomization System, with its production rate exceeding 25 kilograms per hour (kg/h), has shattered all published plasma-atomized production rates for titanium known to its management. 

NA Proactive news snapshot: Todos Medical Ltd, Kainantu Resources Ltd, CleanSpark Inc, Arcadia Biosciences Inc UPDATE …

NA Proactive news snapshot: Todos Medical, Kainantu Resources, CleanSpark, Arcadia Biosciences UPDATE … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Todos Medical Ltd (OTCQB:TOMDF) has announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 clinical trial of antiviral Tollovir for the treatment of hospitalized coronavirus (COVID-19) patients. The trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel, and will evaluate the safety and efficacy of Tollovir, the company said. Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos and NLC Pharma. It is among 3CL protease inhibitors that are targeted as desirable candidates for the development of antiviral therapies against SARS-CoV-2, the virus that causes the COVID-19 disease.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.